385 related articles for article (PubMed ID: 31086947)
21. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2017 Jan; 6(1):12-25. PubMed ID: 27998015
[TBL] [Abstract][Full Text] [Related]
23. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
24. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Int J Gynecol Cancer; 2010 Apr; 20(3):404-10. PubMed ID: 20375805
[TBL] [Abstract][Full Text] [Related]
27. Lot-to-lot consistency study of an
Su YY; Lin BZ; Zhao H; Li J; Lin ZJ; Qiao YL; Wei LH; Hu YM; Li RC; Zhuang SJ; Sun G; Zheng ZZ; Huang SJ; Wu T; Zhang J; Pan HR; Li CG
Hum Vaccin Immunother; 2020 Jul; 16(7):1636-1644. PubMed ID: 31770068
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
29. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG
Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370
[TBL] [Abstract][Full Text] [Related]
31. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
32. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
33. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
Castellsagué X; Muñoz N; Pitisuttithum P; Ferris D; Monsonego J; Ault K; Luna J; Myers E; Mallary S; Bautista OM; Bryan J; Vuocolo S; Haupt RM; Saah A
Br J Cancer; 2011 Jun; 105(1):28-37. PubMed ID: 21629249
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Hu YM; Bi ZF; Zheng Y; Zhang L; Zheng FZ; Chu K; Li YF; Chen Q; Quan JL; Hu XW; Huang XC; Zhu KX; Wang-Jiang YH; Jiang HM; Zang X; Liu DL; Yang CL; Pan HX; Zhang QF; Su YY; Huang SJ; Sun G; Huang WJ; Huang Y; Wu T; Zhang J; Xia NS
Sci Bull (Beijing); 2023 Oct; 68(20):2448-2455. PubMed ID: 37743201
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
Luna J; Plata M; Gonzalez M; Correa A; Maldonado I; Nossa C; Radley D; Vuocolo S; Haupt RM; Saah A
PLoS One; 2013; 8(12):e83431. PubMed ID: 24391768
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
Landier W; Bhatia S; Wong FL; York JM; Flynn JS; Henneberg HM; Singh P; Adams K; Wasilewski-Masker K; Cherven B; Jasty-Rao R; Leonard M; Connelly JA; Armenian SH; Robison LL; Giuliano AR; Hudson MM; Klosky JL
Lancet Child Adolesc Health; 2022 Jan; 6(1):38-48. PubMed ID: 34767765
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
